Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Condition:   Atopic Dermatitis Interventions:   Drug: Placebo;   Drug: AK120 Sponsor:   Akesobio Australia Pty Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials